Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.
Official title: A First-in-human, Multi-center, Randomized, Participant- and Investigator-blinded, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With Charcot-Marie Tooth Type 1A (CMT1A).
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2025-09-30
Completion Date
2028-02-26
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
EDK060, dose A
EDK060, dose A, Single dose, IV infusion
EDK060, dose B
EDK060, dose B, Single dose, IV infusion
EDK060, dose C
EDK060, dose C, Single dose, IV infusion
EDK060, dose D
EDK060, dose D, Single dose, IV infusion
Placebo
Placebo
Locations (3)
Novartis Investigative Site
Ottawa, Ontario, Canada
Montreal Neurological Institute
Montreal, Quebec, Canada
CIUSS de l´Estrie-CHUS- Hôpital Fleurimont
Sherbrooke, Quebec, Canada